Company Overview and News


Add TGTX
to your dashboard

Headline News

TG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Greetings and welcome to the TG Therapeutics’ Third Quarter 2017 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (18-2)

Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success

2017-10-28 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (418-2)

Biotech Forum Daily Digest: Aratana Therapeutics Back In The Spotlight

2017-10-16 seekingalpha
The biotech sector will try to overcome some late weakness last week as trading opens today. (277-3)

Biotech Stock Performance Review -- Cyclacel Pharma, TG Therapeutics, Vericel, and Achaogen

2017-10-09 prnewswire
If you want a Stock Review on CYCC, TGTX, VCEL, or AKAO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. This morning's attention is redirected to the Biotech industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Biotech companies are almost always unprofitable (some suggest that the distinction between "biotech" and "pharmaceutical company" lies in profitability), and many have no real revenue at all. (267-13)

BRIEF-TG Therapeutics says first patient dosed in phase 1 clinical trial evaluating monoclonal antibody​

2017-10-05 reuters
* TG Therapeutics -first patient been dosed in phase 1 clinical trial evaluating safety & tolerability of proprietary fully-human anti-PD-l1 monoclonal antibody​ Source text for Eikon: Further company coverage: (18-1)

3 Things In Biotech You Should Learn Today: August 13, 2017

2017-08-13 seekingalpha
Welcome to another edition of "3 Thing In Biotech You Should Learn Today," the daily digest dedicated to helping you keep up with the latest findings and news from the world of pharmaceuticals and biotechnology.

Week 33 Breakout Forecast: Short-Term Picks To Give You An Edge

2017-08-12 seekingalpha
Last week, two significant volatility streaks for the S&P 500 were ended, but the streak of at least one portfolio stock gaining more than 10% continues past 7 straight weeks. (0-2)

TG Therapeutics' (TGTX) CEO Mike Weiss on Q2 2017 Results - Earnings Call Transcript

2017-08-12 seekingalpha
Greetings, and welcome to the TG Therapeutics Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only-mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?

2017-08-07 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

3 Things In Biotech You Should Learn Today: August 7, 2017

2017-08-07 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest highlighting recent news from the biotechnology and pharmaceutical industries. The goal here is to help forward your due diligence and identify new potential opportunities.

Biotech Bonanza: The Next Leg Up

2017-07-25 seekingalpha
The Biotechnology sector remains one of the top performing sectors this year with the benchmark Nasdaq Biotechnology Index, as represented by ETF (IBB), gaining 17% in the first-half. The index though still remains ~29% down from its all-time high achieved in mid-2015. In comparison, the S&P 500 (SPY) was up 8%, and the Nasdaq Composite (QQQ) up 14%, in the first-half.

2 Small Oncology Stocks That Could Rally Through Year-End

2017-07-21 seekingalpha
Today we revisit two previously positively profiled small cap oncology plays that have been in rally mode recently. (0-2)

A Monetary Policy Reset

2017-07-17 seekingalpha
Monetary policy became more aggressive last month with the announcement of the balance sheet normalization program.

MEI Pharma: Double Trouble Or Double Double?

2017-07-11 seekingalpha
The financial position of the company and the "second" drug in the pipeline are overlooked aspects of MEI Pharma. (0-1)

Stock Research Report

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain an...

Click for full article
CUSIP: 88322Q108